Literature DB >> 32009092

Invasive Tracheobronchial Aspergillosis with Bronchial Ulcers Complicated by Nontuberculous Mycobacterial Disease.

Tomohiro Kanai1, Yumiko Samejima1, Yoshimi Noda1, Sung-Ho Kim1, Kanako Tamura1, Taisei Umakoshi1, Kazunori Shimizu1, Yozo Kashiwa1, Hiroshi Morishita1, Kayo Ueda2, Kunimitsu Kawahara2, Takashi Yaguchi3, Hiroto Matsuoka1.   

Abstract

Invasive tracheobronchial aspergillosis (ITBA) complicated by nontuberculous mycobacteria (NTM) is rare. An 88-year-old man was admitted for hemoptysis. Bronchoscopy revealed bronchial ulcers, and a tissue biopsy showed Aspergillus fumigatus. He was diagnosed with ITBA, which improved with voriconazole. During treatment, infiltrative shadows appeared in his lungs, and bronchoscopy was performed once again. A non-necrotic epithelioid granuloma and Mycobacterium intracellulare were detected in the biopsy specimen. He was diagnosed with NTM disease. It is important to note that tracheobronchial ulcers may cause hemoptysis and to identify the etiology and treat it appropriately when multiple bacteria are found.

Entities:  

Keywords:  bronchial ulcer; hemoptysis; invasive tracheobronchial aspergillosis; non-tuberculous mycobacteria

Mesh:

Substances:

Year:  2020        PMID: 32009092      PMCID: PMC7270761          DOI: 10.2169/internalmedicine.3827-19

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


Introduction

Pulmonary aspergillosis is classified into invasive pulmonary aspergillosis, pulmonary aspergilloma, chronic progressive pulmonary aspergillosis, and allergic bronchopulmonary aspergillosis. Pulmonary aspergillosis rarely but occasionally leads to ulcerative lesions in the trachea and bronchus, and when it does, it is considered to be invasive tracheobronchial aspergillosis (ITBA) (1). In addition, ITBA complicated by nontuberculous mycobacteria (NTM) is rare, although co-infection of Aspergillus and NTM is not uncommon (2). The use of therapeutic agents is limited due to drug interactions. We herein report a case of ITBA with bronchial ulcers and NTM disease.

Case Report

An 88-year-old man visited our hospital due to hemoptysis. He had no history of respiratory diseases and had been admitted to another hospital for the treatment of duodenal ulcer and pyloric stenosis. After his condition improved, he had been discharged but presented with hemoptysis the next day. He was a non-smoker and had worked as a French horn player until 60 years of age. His percutaneous oxygen saturation was 95% (under room air condition). He had no fever, and no abnormalities were detected on a physical examination. A peripheral blood test showed elevated C-reactive protein and proteinase-3 antineutrophil cytoplasmic antibody (PR3-ANCA) (Table 1). Chest X-ray showed small nodular shadows and ground-glass opacities in the right middle and lower lobes (Fig. 1A). High-resolution computed tomography (HRCT) revealed infiltrative and small nodular shadows in both lungs and ground-glass opacities mainly in the right lower lobe (Fig. 1B, C). Hemostatic agents were administered, and hemoptysis improved. However, he had a fever, and hemoptysis recurred on the 11th day of hospitalization.
Table 1.

Laboratory Findings of the Patient.

HematologyBiochemistry
WBC4,500/μLAST30U/L
Neut59.3%ALT42U/L
Lymp27.6%LDH199U/L
Mono8.2%ALP206U/L
Eo4.2%γGTP22U/L
Baso0.7%CK72U/L
Hb11.1g/dLTP6.1g/dL
HCT32.8%ALB3.0g/dL
MCV97flT-Bil0.57mg/dL
PLT20.5×104/μLBUN11.1mg/dL
Cre0.76mg/dL
SerologyNa139mEq/L
CRP1.64mg/dLK3.8mEq/L
ANA<×20BS115mg/dL
MPO-ANCA1.6U/mLIgG1,325mg/dL
PR3-ANCA21.3U/mLIgA601mg/dL
anti-GBM Ab2.6U/mLIgM64mg/dL
β-D-glucan13pg/mL
anti-fungal Ab
CoagulationCandidanegative
PT-INR1.27Aspergillusnegative
APTT35.7sec

WBC: white blood cell, Neut: neutrophil, Ly: lymphocyte, Mo: monocyte, Eo: eosinophil, Ba: basophil, RBC: red blood cell, Hb: hemoglobin, Hct: hematocrit, MCV: mean corpuscular volume, PLT: platelets, PT-INR: prothrombin time-international normalized ratio, APTT: activated partial clotting time, AST: aspartate aminotransferase, ALT: alanine aminotransferase, LDH: lactate dehydrogenase, ALP: alkaline phosphatase, γ-GTP: γ-glutamyl transpeptidase, TP: total protein, ALB: albumin, T-Bil: total bilirubin, BUN: blood urea nitrogen, Cre: creatinine, BS: blood sugar, CRP: C-reactive protein, ANA: antinuclear antibody, anti-dsDNA Ab: anti-double-stranded DNA antibody

Figure 1.

Chest X-ray showed small nodular shadows and ground-glass opacities in the right middle and lower lobes (A). High-resolution computed tomography revealed infiltrative and small nodular shadows in both lungs and ground-glass opacities in the right lower lobe (B and C) (arrowheads).

Laboratory Findings of the Patient. WBC: white blood cell, Neut: neutrophil, Ly: lymphocyte, Mo: monocyte, Eo: eosinophil, Ba: basophil, RBC: red blood cell, Hb: hemoglobin, Hct: hematocrit, MCV: mean corpuscular volume, PLT: platelets, PT-INR: prothrombin time-international normalized ratio, APTT: activated partial clotting time, AST: aspartate aminotransferase, ALT: alanine aminotransferase, LDH: lactate dehydrogenase, ALP: alkaline phosphatase, γ-GTP: γ-glutamyl transpeptidase, TP: total protein, ALB: albumin, T-Bil: total bilirubin, BUN: blood urea nitrogen, Cre: creatinine, BS: blood sugar, CRP: C-reactive protein, ANA: antinuclear antibody, anti-dsDNA Ab: anti-double-stranded DNA antibody Chest X-ray showed small nodular shadows and ground-glass opacities in the right middle and lower lobes (A). High-resolution computed tomography revealed infiltrative and small nodular shadows in both lungs and ground-glass opacities in the right lower lobe (B and C) (arrowheads). Bronchial arteriography was performed on the 13th day. The bronchial arteries were dilated bilaterally, which indicated chronic airway infection. Bronchial artery embolization (BAE) was performed with gelatin sponges, and the hemoptysis improved. Bronchoscopy was performed on the 18th day to investigate the cause of hemoptysis, revealing multiple bronchial ulcers and flares of bronchial mucosa on both bronchi (Fig. 2A-C). Samples were collected from the aspiration sputum, followed by the bronchial lavage fluid and bronchial tissue around the ulcers (obtained by a biopsy). Pseudomonas aeruginosa and NTM were detected in all samples, and Aspergillus was detected only in the culture of the bronchial tissue around ulcers. NTM was detected from all samples. Mycobacterium intracellulare was identified through the culture examination and through polymerase chain reaction of the biopsy specimen.
Figure 2.

Bronchoscopy on the 18th hospital day revealed multiple bronchial ulcers and bronchitis (A-C). A biopsy was performed on the ulcerative lesions (arrows). Bronchoscopy on the 46th day showed partial improvement of bronchial ulcers and flares (D-F). On the 46th day, the ulcerative lesions and flares had improved (G-I). (A), (D), and (G): Left superior bronchus, (B), (E) and (H): right superior bronchus, (C), (F), and (I): right middle and lower bronchus.

Bronchoscopy on the 18th hospital day revealed multiple bronchial ulcers and bronchitis (A-C). A biopsy was performed on the ulcerative lesions (arrows). Bronchoscopy on the 46th day showed partial improvement of bronchial ulcers and flares (D-F). On the 46th day, the ulcerative lesions and flares had improved (G-I). (A), (D), and (G): Left superior bronchus, (B), (E) and (H): right superior bronchus, (C), (F), and (I): right middle and lower bronchus. Although a cytological examination revealed filamentous fungi, a histological examination of the biopsy specimen revealed neutrophil infiltration, necrotic tissue and epithelial defects without fungus. A histological examination revealed no granuloma that were suggestive of NTM disease. Since Aspergillus was detected in the culture of the bronchial tissue around the ulcers, he was diagnosed with ITBA. He was treated with voriconazole (VRCZ) from the 24th day, and his symptoms gradually improved. VRCZ was later changed to itraconazole (ITCZ) as he lost appetite. On the 40th day, however, he had a fever once again, and HRCT revealed multiple patchy infiltrative shadows. In order to observe the bronchial ulcers and investigate the etiology of the fever and the new shadows, bronchoscopy was performed again on the 46th day. It showed partial improvement of the bronchial ulcers and flares (Fig. 2D-F). A biopsy was performed on the lung field, and a histological examination of the biopsy specimen revealed non-necrotizing epithelioid granuloma with fibrin deposition, swelling of alveolar epithelium and lymphocyte infiltration. Polymerase chain reaction of the biopsy specimen for M. intracellulare was positive, so the new infiltrative shadows were diagnosed as NTM disease. On the 53rd day, in addition to ITCZ, he was treated with clarithromycin (CAM) and ethambutol (EB) without rifampicin (RFP) due to drug interactions. The infiltrative shadows and fever improved after addition of CAM and EB. On the 88th day, bronchoscopy was performed, which showed the complete healing of the bronchial ulcers (Fig. 2G-I.)

Discussion

We encountered a case of ITBA with bronchial ulcers followed by NTM disease (1). To our knowledge, seven cases of ITBA have been published in Japan (3-9); these cases were identified using the keywords “invasive tracheobronchial aspergillosis” or “aspergillus tracheobronchitis” in the PubMed database (Table 2).
Table 2.

Summary of the Published Cases of Invasive Tracheobronchial Aspergillosis.

Age, yearsSexSymptomsComplicationsDiagnosisPre-immunosuppressive therapyTreatmentOutcomeCause of deathReference No.
44FCough, FeverCML GVHDHistrogical examination CultureBone marrow transplantation Steroid pulse therapy MetylprednisoloneAMPH-BDeadRespiratory failure3
91FDyspneaSFTSHistrogical examination CultureNoMCFG VRCZAlive4
69FCough, DyspneaMLCytological examination CultureChemotherapy RadioimmunotherapyL-AMB ITCZDeadML5
44FFeverEPHistological examination CultureOral corticosteroidL-AMB VRCZ CPFGDeadARDS6
45MDyspnea, Polyarthralgia Fever, weight lossSLE, DMHistrogical examination CultureNoITCZ+VRCZ(oral) VRCZ+MCFGDeadSLE, DM7
61FDiarrheaMG, CKDHistrogical examination CultureNoVRCZAlive8
57FRespiratory failureFulminant hepatitis HPSHistrogical examination CultureSteroid pulse therapyVRCZ+CPFGDeadARDS9
43FDyspnea, SputumLAMHistrogical examination CultureLung transplantation Deflazacort, TAC and MMFAMPH-B VRCZDeadRecurrent LAM10
23MCough, DyspneaAAHistological examinationAllogeneic HSCTL-AMB PSCZ+CPFGAlive11
45MCough, Rhinorrhea HeadacheAIDS with HARRT Neutropenia DLBCL (CR)Histlogical examination CultureNoAMPH-B VRCZDeadRespiratory failure12
42MCoughTuberculosis scar Diabetes mellitusCultureNoAMPH-B ITCZAlive13
60MChiefly, Chest pain Fever, CoughInfluenzaeHistological examinationNoVRCZAlive14

CML: chronic myelocytic leukemia, GVHD: graft versus host disease, SFTS: severe fever with thrombocytopenia syndrome, ML: malignant lymphoma, EP: eosinophilic pneumonia, SLE: systemic lupus erythematosus, DM: dermatomyositis, MG: monoclonal gammopathy, CKD: chronic kidney disease, HPS: hemophagocytic syndrome, LAM: lymphangioleiomyomatosis, AA: aplastic anemia, AIDS: acquired immunodeficiency syndrome, DLBCL: diffuse large B-cell lymphoma, CR: complete remission, TAC: tacrolimus., MMF: mycophenolate Mofetil, HSCT: hematopoietic stem cell transplantation, AMPH-B: amphotericin B, L-AMB: liposomal amphotericin B, VRCZ: voriconazole, PSCZ: posaconazole, ITCZ: itraconazole, CPFG: caspofungin, MCFG: micafungin, ARDS: acute respiratory distress syndrome

Summary of the Published Cases of Invasive Tracheobronchial Aspergillosis. CML: chronic myelocytic leukemia, GVHD: graft versus host disease, SFTS: severe fever with thrombocytopenia syndrome, ML: malignant lymphoma, EP: eosinophilic pneumonia, SLE: systemic lupus erythematosus, DM: dermatomyositis, MG: monoclonal gammopathy, CKD: chronic kidney disease, HPS: hemophagocytic syndrome, LAM: lymphangioleiomyomatosis, AA: aplastic anemia, AIDS: acquired immunodeficiency syndrome, DLBCL: diffuse large B-cell lymphoma, CR: complete remission, TAC: tacrolimus., MMF: mycophenolate Mofetil, HSCT: hematopoietic stem cell transplantation, AMPH-B: amphotericin B, L-AMB: liposomal amphotericin B, VRCZ: voriconazole, PSCZ: posaconazole, ITCZ: itraconazole, CPFG: caspofungin, MCFG: micafungin, ARDS: acute respiratory distress syndrome ITBA is a rare form of invasive pulmonary aspergillosis. In previous reports, immunocompromised patients, such as those who had received organ or bone marrow transplantation, those being treated with immunosuppressive agents such as steroids and those suffering from acquired immunodeficiency syndrome, were diagnosed with ITBA (6,10-12). The symptoms are usually non-specific, such as cough, dyspnea and respiratory failure (9,13,14). Although we were unable to identify cases in which the main symptom was hemoptysis, hemoptysis is also a non-specific symptom. We considered ANCA-related vasculitis, NTM disease and adverse effects of BAE as potential causes of the bronchial ulcers in addition to ITBA. We rejected ANCA-related vasculitis and NTM disease because the patient had no abnormalities in any part of the body except the bronchus and there was no epithelioid granuloma in the biopsy specimen of the bronchial ulcers (15,16). BAE is a treatment of hemoptysis that may rarely cause bronchial necrosis, stenosis or ischemia (17-19). Ivanick et al. reported a case of bronchial necrosis after BAE with alcohol as an embolic material. They considered that bronchial necrosis occurred due to obstruction of bronchopulmonary anastomoses because alcohol has a low viscosity (20). However, in the present case, gelatin sponges were used, and their diameter was not considered so small as to obstruct the bronchopulmonary anastomoses. We suspected that the bronchial ulcers had existed before BAE because hemoptysis was recognized before BAE, and HRCT revealed no shadows that might have caused hemoptysis. Aspergillus was detected only in culture, and the ulcerative lesions improved despite being treated only with antifungal therapy until the second bronchoscopy procedures. Based on these findings, we diagnosed the patient with ITBA. Not only severely immunocompromised but also mildly immunocompromised patients, such as those with malignancies, chronic obstructive pulmonary disease, chronic kidney disease and diabetes mellitus, can also develop ITBA (1,5,13,21). In addition to A. fumigatus, P. aeruginosa and NTM were detected in the respiratory tract despite the patient not being immunosuppressed. Co-infection with Aspergillus and NTM is not rare, but the patient had no underlying diseases with structural changes in the lung, such as bronchiectasis, pulmonary emphysema or interstitial pneumonia, and no history of the long-term administration of antibiotics. King et al. reported that a bagpipe player died of hypersensitivity pneumonitis and found a large number of bacteria in the instrument he had used (22). In our case, the patient had worked as a French horn player until 60 years of age. Although roughly 30 years had passed since he retired and the pathophysiology differed from hypersensitivity pneumonitis, constant inhalation of the bacteria in the instrument may have resulted in the co-infection of Aspergillus and NTM. In patients with mycobacterium avium complex (MAC) infections, the cytokine profiles in peripheral blood, programmed death-1 (PD-1) expression and apoptosis of lymphocytes are different from those of controls (23,24). Shu et al. reported that the PD-1 and PD-ligand 1 expression and apoptosis of lymphocytes in patients with MAC were higher than in those without MAC (24). Kwon et al. reported a case of ITBA after influenza infection and the possibility of cell-mediated defect, disruption of normal ciliary clearance and leukopenia as a cause of ITBA in an immunocompetent patient (14). Co-infection with other infectious diseases may affect the host immunity. In this case, NTM may have suppressed the patient's immune system, which could have induced ITBA. He was also diagnosed with gastric cancer when examined due to a loss of appetite after his discharge from our hospital, so malignancy may also have affected ITBA. Wu et al. reported that the average duration of treatment for ITBA was 25 days (25). There is no evidence suggesting whether or not monotherapy is adequate for ITBA. Although combination therapy of anti-fungal agents has been reported (7), ITBA has also been completely cured by monotherapy alone (4,8,21). In the present case, we treated him with antifungal drugs for 56 days and changed the antifungal drugs several times due to his loss of appetite. We completed treatment with monotherapy after confirming the improvement of bronchial ulcers and disappearance of Aspergillus. In addition to Aspergillus, we needed to treat NTM disease. Although it is difficult to use RFP due to its interaction with VRCZ, Miwa et al. reported that a two-drug regimen (CAM and EB) for the treatment of NTM disease was not inferior to a three-drug regimen (CAM, EB, and RFP), and the occurrence of adverse events in the two-drug regimen tended to be lower than that in the three-drug regimen (26).

Conclusion

We reported a case of ITBA with bronchial ulcers complicated by NTM disease. Tracheobronchial ulcers must be considered as a cause of hemoptysis. It is important to identify the etiology based on pathological and bacteriological examinations in order to treat overlapping chronic respiratory tract infection appropriately.

The authors state that they have no Conflict of Interest (COI).
  26 in total

1.  Bronchial artery embolization for hemoptysis.

Authors:  David R Sopko; Tony P Smith
Journal:  Semin Intervent Radiol       Date:  2011-03       Impact factor: 1.513

2.  Invasive Pulmonary Aspergillosis Presenting with Tracheobronchial Involvement.

Authors:  Hisako Kushima; Issei Tokimatsu; Hiroshi Ishii; Jun-Ichi Kadota
Journal:  Intern Med       Date:  2016-06-15       Impact factor: 1.271

Review 3.  Aspergillus tracheobronchitis after allogeneic bone marrow transplantation.

Authors:  U Machida; M Kami; Y Kanda; K Takeuchi; M Akahane; I Yamaguchi; C Kakiuchi; N Takeda; Y Tanaka; S Chiba; H Honda; H Hirai
Journal:  Bone Marrow Transplant       Date:  1999-11       Impact factor: 5.483

4.  Tracheobronchial aspergillosis following primary cutaneous aspergillosis in a lung-transplant recipient.

Authors:  Woo Hyun Cho; Ji Eun Kim; Doo Soo Jeon; Yun Seong Kim; Hyun Woo Chin; Dong Hoon Shin
Journal:  Intern Med       Date:  2011-01-15       Impact factor: 1.271

5.  Efficacy of clarithromycin and ethambutol for Mycobacterium avium complex pulmonary disease. A preliminary study.

Authors:  Seiichi Miwa; Masahiro Shirai; Mikio Toyoshima; Toshihiro Shirai; Kazumasa Yasuda; Koshi Yokomura; Takashi Yamada; Masafumi Masuda; Naoki Inui; Kingo Chida; Takafumi Suda; Hiroshi Hayakawa
Journal:  Ann Am Thorac Soc       Date:  2014-01

6.  Isolated invasive Aspergillus tracheobronchitis: a clinical study of 19 cases.

Authors:  N Wu; Y Huang; Q Li; C Bai; H-D Huang; X-P Yao
Journal:  Clin Microbiol Infect       Date:  2009-08-18       Impact factor: 8.067

7.  The risk factors for developing of chronic pulmonary aspergillosis in nontuberculous mycobacteria patients and clinical characteristics and outcomes in chronic pulmonary aspergillosis patients coinfected with nontuberculous mycobacteria.

Authors:  Kazuaki Takeda; Yoshifumi Imamura; Takahiro Takazono; Masataka Yoshida; Shotaro Ide; Katsuji Hirano; Masato Tashiro; Tomomi Saijo; Kosuke Kosai; Yoshitomo Morinaga; Shigeki Nakamura; Shintaro Kurihara; Misuzu Tsukamoto; Taiga Miyazaki; Takayoshi Tashiro; Shigeru Kohno; Katsunori Yanagihara; Koichi Izumikawa
Journal:  Med Mycol       Date:  2015-11-03       Impact factor: 4.076

Review 8.  Tracheobronchial manifestations of Aspergillus infections.

Authors:  Rafal Krenke; Elzbieta M Grabczak
Journal:  ScientificWorldJournal       Date:  2011-11-20

9.  Invasive tracheobronchial aspergillosis developed during radioimmunotherapy for malignant lymphoma.

Authors:  Shuku Sato; Yotaro Tamai; Hideyasu Sugimoto; Shinji Watanabe; Tomohiro Kumagae; Emiko Kannbe; Eri Tanaka
Journal:  Clin Case Rep       Date:  2018-03-04

10.  Pseudomembranous Invasive Tracheobronchial Aspergillosis with Fulminant Hepatitis and Hemophagocytic Syndrome.

Authors:  Suguru Majima; Shotaro Okachi; Motoyo Asano; Keiko Wakahara; Naozumi Hashimoto; Mitsuo Sato; Masatoshi Ishigami; Yoshinori Hasegawa
Journal:  Intern Med       Date:  2018-03-30       Impact factor: 1.271

View more
  1 in total

1.  Case Report: Sudden Fatal Hemorrhage in Ulcerative Fungal Laryngotracheitis-A Pediatric Case Report.

Authors:  Andrea Porzionato; Elena Stocco; Aron Emmi; Veronica Macchi; Raffaele De Caro
Journal:  Front Pediatr       Date:  2022-01-11       Impact factor: 3.418

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.